Speaker Presentations

Developing RNA based approaches for the treatment of Pompe Disease and neurodegenerative conditions
Emanuele Buratti, Group Leader, Molecular Pathology Lab, ICGEB, Italy

DELiveri: Massive throughput screens to identify conjugates that promote cell delivery of nucleic acid therapeutics
Yaniv Erlich, CEO and Co-founder, Eleven Therapeutics, IL

RNA-binding proteins in melanoma progression
Fatima Gebauer, President of the RNA Society and Principal Investigator, Center for Genomic Regulation (CRG), Spain

Nucleic Acid Therapeutic Unlabeled Reporter Assay (NATURA): A novel platform for high-throughput quantification of NATs’ functional delivery and potency
Ernesto Guccione, Principal Investigator, The Guccione Lab, Icahn School of Medicine at Mount Sinai, USA

AI-Driven Design: Unlocking Novel Mechanisms in RNA Therapeutics
Tamar Grossman, CEO, La Jolla Labs, USA

SpliSense – A transformative RNA (ASOs) based company for the treatment of Pulmonary diseases
Gili Hart, SpliSense, IL

SRSF1-regulated alternative splicing controls on oncogenic circuit in pancreatic cancer
Adrian Krainer, Cold Spring Harbor Laboratory, New York, USA

Dual-function oligonucleotide strategies for immunotherapy of acute myeloid leukemia
Marcin Kortylewski, Principal Investigator, The Kortylewski Lab City of Hope, USA

Exploiting the dark genome to target drug-tolerant cells and improve anticancer immune therapies
Eleonora Leucci, Principal Investigator – RNA Cancer Biology Lab, KU Leuven, Belgium

Rewriting the Message: RNA Splice Disruption Unmasks New Cancer Immunotherapy Targets
Michal Lotem, Head of The Hadassah Cancer Reseaarch Institute (HCRI), Hadassah Hebrew University Medical Center, Jerusalem, IL

Targeting m6A-RNA Biology in FTO-Dependent Cancers
Amir Mor, CSO, RNAble, IL

Harnessing RNA-Driven Intelligence to Revolutionize Personalized Cancer Therapy
Aron Popovtzer, Director of the Sharett Institute of Oncology, Hadassah Medical Center, Jerusalem, IL

Therapeutic approaches for HNRNPH2-Related Neurodevelopmental Disorder, an ultra-rare neurogenetic disorder
Christopher Ricupero, Assistant Professor, Columbia University Irving Medical Center, USA

Exploiting RNA translation control to fight cancer resistance
Caroline Robert, Head of Dermatology, Gustave Roussy Institute, France

Translation dysregulation in cancer as a source for targetable antigens
Yardena Samuels, Director, Moross Integrated Cancer Center, Samuels Lab, Weizmann Institute of Science, IL

Modeling and modulating antitumor immunity with RNA nanoparticles in 3D-bioprinted tumoroids
Ronit Satchi-Fainaro, Director, Cancer Biology Research Center, and Director, TAU Kahn 3D BioPrinting Initiative
TAU, IL

Splicing dysregulation: hallmark and therapeutic opportunity in cancer
Claudio Sette, Principal Investigator, Catholic University of the Sacred Heart, School of Medicine, Italy

Pseudoexon activation as a therapeutic approach
Brage Storstein Andresen, Head of Research, Brage Storstein Andresen Lab, University of Southern Denmark

Aberrantly spliced cancer proteoforms: if you can’t beat them, eat them!
Andrei Thomas-Tikhonenko, Director of Experimental Pathology, Children’s Hospital of Philadelphia, USA

Targeting noncoding elements to boost haploinsufficient gene expression
Igor Ulitsky, Principal Investigator, Ulitsky Lab, Weizmann Institute of Science, IL

miRNA-based logic circuits encoded on self-amplifying RNA for highly specific cancer cell classification
Ron Weiss, Principal Investigator, The Weiss Lab, Massachusetts Institute of Technology, Boston, USA